• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微球胰腺补充剂的体内和体外研究。

In vivo and in vitro studies of microsphere pancreatic supplements.

作者信息

Littlewood J M, Kelleher J, Walters M P, Johnson A W

机构信息

Regional Cystic Fibrosis Unit, St. James's University Hospital, Leeds, U.K.

出版信息

J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S22-9. doi: 10.1097/00005176-198811001-00006.

DOI:10.1097/00005176-198811001-00006
PMID:2457072
Abstract

Over the past 5 years, the Leeds Regional Cystic Fibrosis (CF) Unit has provided comprehensive annual assessments of CF patients that include dietary assessments and fat absorption studies. Enteric-coated microsphere pancreatic enzyme preparations (microsphere preparations) were compared to conventional enzymes as therapeutic agents for these patients. Presently in the U.K., two microsphere preparations are licensed for use and a further two products are likely to receive licenses in the near future. The success of these preparations is dependent on the ability of the microsphere coating to resist dissolution until the pH exceeds approximately 5.5 and thus prevent inactivation of lipase in the acid environment of the stomach. A study comparing Pancrex V Forte, a conventional enzyme preparation, to three microsphere preparations, Pancrease, Creon, and pancreatin Merck, confirmed the superiority of Pancrease and Creon over Pancrex V Forte and pancreatin Merck with regard to control of symptoms, and nitrogen and fat absorption. Because of differences in the physical characteristics of various microsphere preparations, the dissolution rates of Pancrease, Creon, and pancreatin Merck were compared in vitro. In aqueous buffers, striking differences among the preparations were seen at pH 5.5; whereas only 25% of available lipase was released from Creon, both Pancrease and pancreatin Merck show almost complete dissolution at this pH. Only at pH 6.5 and above do all three preparations show complete dissolution. In duodenal juice, as in aqueous buffers, lipase release from Creon takes place at a lower rate than with the other two preparations until pH 6.0 or higher is attained.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在过去5年里,利兹地区囊性纤维化(CF)治疗中心对CF患者进行了全面的年度评估,其中包括饮食评估和脂肪吸收研究。将肠溶微球胰酶制剂(微球制剂)与传统酶制剂作为这些患者的治疗药物进行了比较。目前在英国,有两种微球制剂已获许可使用,另外两种产品可能在不久的将来获得许可。这些制剂的成功取决于微球包衣在pH值超过约5.5之前抵抗溶解的能力,从而防止脂肪酶在胃酸环境中失活。一项将传统酶制剂Pancrex V Forte与三种微球制剂Pancrease、Creon和胰酶默克进行比较的研究证实,在症状控制、氮和脂肪吸收方面,Pancrease和Creon优于Pancrex V Forte和胰酶默克。由于各种微球制剂物理特性的差异,对Pancrease、Creon和胰酶默克的溶解速率进行了体外比较。在水性缓冲液中,在pH 5.5时制剂之间出现了显著差异;虽然Creon中只有25%的可用脂肪酶释放出来,但Pancrease和胰酶默克在该pH值下几乎完全溶解。只有在pH 6.5及以上时,三种制剂才会完全溶解。在十二指肠液中,与水性缓冲液一样,直到达到pH 6.0或更高,Creon中脂肪酶的释放速率低于其他两种制剂。(摘要截短于250字)

相似文献

1
In vivo and in vitro studies of microsphere pancreatic supplements.微球胰腺补充剂的体内和体外研究。
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S22-9. doi: 10.1097/00005176-198811001-00006.
2
Comparison of four pancreatic extracts in cystic fibrosis.四种胰腺提取物在囊性纤维化中的比较。
Arch Dis Child. 1987 Jun;62(6):564-8. doi: 10.1136/adc.62.6.564.
3
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.补充胰酶对囊性纤维化患儿的疗效:通过随机交叉研究比较两种制剂,并对同一组患者在两个不同年龄进行回顾性研究。
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S40-5.
4
In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values.
Aliment Pharmacol Ther. 1996 Oct;10(5):771-5. doi: 10.1046/j.1365-2036.1996.55197000.x.
5
A comparison of two pancreatin microsphere preparations in cystic fibrosis.囊性纤维化中两种胰酶微球制剂的比较。
N Z Med J. 1992 Mar 25;105(930):107-8.
6
Pancrease gastroresistance: in vitro evaluation of pH-determined dissolution.胰腺胃耐受性:pH值测定溶解的体外评估
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S18-21.
7
Pancreatin preparations used in the treatment of cystic fibrosis--lipase content and in vitro release.用于治疗囊性纤维化的胰酶制剂——脂肪酶含量及体外释放情况
Aliment Pharmacol Ther. 1996 Jun;10(3):433-40. doi: 10.1111/j.0953-0673.1996.00433.x.
8
In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.三种胰酶制剂的体外比较研究:溶出曲线、活性酶释放及酸稳定性
Aliment Pharmacol Ther. 2008 Feb 1;27(3):283-92. doi: 10.1111/j.1365-2036.2007.03563.x. Epub 2007 Oct 28.
9
Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres.肠溶微球中膳食脂肪与胰酶的十二指肠递送不匹配。
Pancreas. 1997 Oct;15(3):226-35. doi: 10.1097/00006676-199710000-00003.
10
Two enteric coated microspheres in cystic fibrosis.囊性纤维化中的两种肠溶微球。
Arch Dis Child. 1990 Jun;65(6):594-7. doi: 10.1136/adc.65.6.594.

引用本文的文献

1
Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines.胰腺外分泌功能不全管理共识:英国实用指南
BMJ Open Gastroenterol. 2021 Jun;8(1). doi: 10.1136/bmjgast-2021-000643.
2
Pancreatic enzyme replacement therapy for people with cystic fibrosis.针对囊性纤维化患者的胰酶替代疗法。
Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD008227. doi: 10.1002/14651858.CD008227.pub4.
3
Pancreatic enzyme replacement therapy for people with cystic fibrosis.针对囊性纤维化患者的胰酶替代疗法。
Cochrane Database Syst Rev. 2016 Nov 23;11(11):CD008227. doi: 10.1002/14651858.CD008227.pub3.
4
Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.21世纪用于胰腺外分泌功能不全的胰酶替代疗法。
World J Gastroenterol. 2014 Sep 7;20(33):11467-85. doi: 10.3748/wjg.v20.i33.11467.
5
In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.肠溶包衣胰酶制剂的物理参数、酶活性、耐酸性和pH溶解特性的体外比较:对临床变异性和药学替代的影响
J Pediatr Pharmacol Ther. 2007 Apr;12(2):115-28. doi: 10.5863/1551-6776-12.2.115.
6
Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis.
Dig Dis Sci. 1998 Jan;43(1):203-13. doi: 10.1023/a:1018813229334.
7
Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.在囊性纤维化患者中,胰腺补充奥美拉唑后粪便脂肪排泄的改善与胰腺残余外分泌功能有关。
Dig Dis Sci. 1993 Jan;38(1):1-6. doi: 10.1007/BF01296765.
8
Abdominal pain in cystic fibrosis.囊性纤维化中的腹痛
J R Soc Med. 1995;88 Suppl 25(Suppl 25):9-17.
9
Gastrointestinal complications in cystic fibrosis.囊性纤维化的胃肠道并发症
J R Soc Med. 1992;85 Suppl 19(Suppl 19):13-9.
10
Enzyme contents of pancreatic extract preparations. Are they optimal?
Drugs. 1992 Nov;44(5):685-9. doi: 10.2165/00003495-199244050-00001.